Incyte

Company Overview

Incyte is focused on discovering, developing, and selling novel medicines in oncology and hematology. The company operates through a unified business structure and maintains a broad portfolio and pipeline of targeted therapies and immunotherapies. Its oncology portfolio includes Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease. The company sells Pemazyre, a targeted therapy for cholangiocarcinoma, and Monjuvi (developed in collaboration with MorphoSys) for diffuse large B-cell lymphoma. The pipeline portfolio includes drugs for treating lung cancer, graft versus host disease, B-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies.

Financial Highlights (FY 2025)

Company's Business Segments

• Cancer Therapeutics : The company develops and sells prescription medicines, primarily in oncology (blood cancers and solid tumors) and in inflammation and autoimmunity (skin conditions such as atopic dermatitis and vitiligo).